MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Status:
Not yet recruiting
Trial end date:
2028-09-30
Target enrollment:
Participant gender:
Summary
To determine the maximum tolerated dose (MTD) of FT538 monotherapy when administered via
intraperitoneal (IP) catheter and in combination with intravenous (IV) enoblituzumab in
patients with recurrent ovarian, fallopian tube, and primary peritoneal cancer.